Insilico Medicine will present its latest advances in generative AI-driven drug discovery, quantum-enabled research, and clinical development at the BIO 2026 International Convention in San Diego. The company will participate in three featured speaking sessions covering China’s impact on biotech business development, quantum computing in drug discovery, and strategies for building smarter pipelines for challenging targets. Insilico will also showcase its Pharma.AI platform, LifeStar 2 laboratory, and MMAI Gym for Science while meeting with biopharma partners, investors, and researchers at Booth #4021.

Insilico highlighted progress across its growing pipeline, including Rentosertib, the world’s first AI-discovered anti-fibrotic candidate with a novel mechanism of action, which has completed a Phase 2a proof-of-concept trial. The company also shared updates on ISM5411 for inflammatory bowel disease and multiple oncology programs that have reached first-in-patient dosing. Since its founding in 2014, Insilico has published more than 200 peer-reviewed papers and was recently recognized among the top global corporate research institutions in Nature Index rankings.

Global type 1 diabetes (T1DM) burden among children and adolescents aged 0–19 increased during 1990–2021. Incidence rose from 2.71 to 7.42 per 100,000 and prevalence from 20.75 to 56.59 per 100,000. Mortality and YLLs also increased, indicating worsening fatal outcomes. North America and Europe had the highest incidence and prevalence in 2021. Inequalities widened, with poorer countries bearing a growing and disproportionate burden of T1DM mortality and YLLs.